Abstract library

1562 results for "case study".
#2848 Correlation between Clinicopathological Features and Distant Metastases in Pancreatic Neuroendocrine Neoplasm: A National Multicenter 10-Year Retrospective Study
Introduction: The incidence of pancreatic neuroendocrine neoplasm (PNEN) is increasing, and the prognosis of patients with PNEN is quite different.So, it is of great significance to study the effect of different pathological features on the prognosis of patients with PNEN.
Conference: 17th Annual ENETS Conference (2020)
Category: Biomarkers
Presenting Author: Xinyi Zhu
Authors: Zhu X, Yang H, Lu H, Shi S, ...
#154 Long-term disease stabilization in a patient with advanced pancreatic neuroendocrine tumor treated with combined everolimus and octreotide LAR after prior failure of cytotoxic therapy
Introduction: Targeting of multiple pathways has become an important strategy for improved tumor control in metastatic neuroendocrine tumors (NETs). Among these targets is the mammalian target of rapamycin (mTOR), a central regulator of cell growth, proliferation, and apoptosis, which is blocked by everolimus, an oral inhibitor of mTOR that has shown efficacy in patients with metastatic pancreatic NETs. Recent evidence has suggested that suppression of insulin-like growth factor-1 receptor (IGF-1R) secretion with octreotide therapy, along with concurrent inhibition of mTOR by everolimus, may improve tumor control synergistically by preventing feedback activation of the PI3K/Akt/mTOR pathway.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Alexandre Teulé Vega
#864 Diagnostic and Outcome Differences between Sporadic and Familial Cases of Medullary Thyroid Cancer: A Retrospective Cohort Study
Introduction: Hereditary Medullary Thyroid Cancer (MTC) accounts for 20-30% of cases and has some clinically relevant peculiarities.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Guillermo Ropero Luis
#865 Diagnostic and Outcome Differences between Sporadic and Familial Cases of Pheochromocytoma and Paraganglioma: A Retrospective Cohort Study
Introduction: Hereditary Pheochromocytomas (PCC) and Paragangliomas (PGL) account for 30-35% of cases and have some clinically relevant peculiarities.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Guillermo Ropero Luis
#1346 A Nation-Wide Retrospective Epidemiological Study of Gastroenteropancreatic Neuroendocrine Neoplasms in China
Introduction: Representative data on the gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) in Chinese patients is rare.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Zhang Yu-Qing
#2726 Clinicopathological Characterization of Gastroenteropancreatic Neuroendocrine Tumors in a Single Institute of North Africa: A Retrospective Study of 80 Cases
Introduction: The management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) is based on a variety of factors including stage, anatomic location, and the presence and type of symptoms.
Conference: 17th Annual ENETS Conference (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Imen Harhira
#53 The rise and fall of chromogranin A as an indicator for NET
Introduction: There is now general awareness that treatment with proton pump inhibitors (ppi) may cause moderate rises in circulating concentrations of gastrin and/or chromogranin A (CgA), thus decreasing the specificity of these markers in the diagnosis of neuroendocrine tumors (NETs). Due to their high efficacy, proton pump inhibitors (ppi) are one of the most frequently prescribed classes of drugs worldwide. Several studies in various countries report that 30% or more of in-patients have been prescribed ppi. Patients who are suspected of having a neuroendocrine tumor (NET) often have gastrointestinal (GI) symptoms for which ppi are prescribed and therefore they may be already taking ppi when their first blood sample is assayed for NET markers. We previously encountered a case of extreme rise in CgA which flagged the possibility of a NET, but was later shown to be due to ppi therapy alone. We present CgA and gastrin data in relation to ppi therapy and withdrawal for this patient. In order to see if this was an isolated incident, we audited all laboratory requests for CgA/gastrin in a two-year period and monitored those that provided details of ppi treatment/withdrawal.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Lee Armstrong
Authors: Armstrong L, Ryan K, Ardill J, ...
#495 Risk Factors for Sporadic Pancreatic Neuroendocrine Tumors (PNETs): Updated Results From a Single-Center Case Control Study
Introduction: PNETs are uncommon and little is known about risk factors and association with other cancers.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Thorvardur Halfdanarson
#1103 Risk and Protective Factors for Midgut Carcinoid Tumours: A Case-Control Study of Prospectively Evaluated Patients
Introduction: The incidence of midgut carcinoid tumours is on the rise, but few studies have investigated risk factors for their occurrence.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Doctor Maria Rinzivillo
#1918 Case Study: Immunotherapy in a Young Adult with Atypical Neuroendocrine Tumour
Introduction: Use of immunotherapy PD-1 antibody has emerged as a novel therapeutic option for treating multiple solid tumors. In the setting of neuroendocrine tumors (NETs), little is known. Currently, trials are underway investigating its use in high-grade NETs, but outcomes remain to be seen
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: Miranda Stavrides-Eid
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss on any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team